

Analysis of the distribution of mRS scores in the Modified-Intent-to-Treat (MITT) population using imputed data

Page 1 of 6

	Placebo	Natalizumab	OR (a)	Two-sided 90% Confidence Interval	One-sided p-value (b)
Number of subjects in the MITT population	82	77			
Day 5	82 (100)	76 (100)	0.89	[ 0.55, 1.45]	0.564
0	0	2 ( 3)			
1	3 ( 4)	2 ( 3)			
2	10 ( 12)	11 ( 14)			
3	13 ( 16)	11 ( 14)			
4	25 ( 30)	16 ( 21)			
5	29 ( 35)	31 ( 41)			
6	2 ( 2)	3 ( 4)			

Note: The MITT population is defined as all subjects who were randomized and have received the entire infusion of study treatment.

(a)Odds ratio from a proportional-odds logistic regression model assuming a common odds ratio across all cut points of the mRS score. Covariates include baseline DWI volume (< median vs >= median), treatment time window, location of stroke abnormality (cortical/subcortical), and tPA use (yes/no).

(b)P-value based on Van Elteren's test, adjusting for baseline DWI volume (< median vs >= median), treatment time window, location of stroke abnormality (cortical/subcortical), and tPA use (yes/no).